KSIX Completes Much Anticipated Agreement with True Wireless

LAS VEGAS, NV — (Marketwired) — 07/24/17 — KSIX Media Holdings, Inc. (OTCBB: KSIX) “The Company”, announced the signed equity agreement with True Wireless. The company will immediately begin managing True Wireless adding over $1.1 million dollars to the company’s monthly revenue.

Under the agreement, control of the company has shifted to Brian Cox. Cox brings an experienced team of blue chip accounting, legal, sales and operations teams. Cox noted, “The first step in my plan is to get KSIX Holdings’ combined revenues to over $2 Million a month. Operationally, we will be reorganizing to increase the company’s efficiency. We will synergize the KSIX-TRUE team so everyone has a specialized role with laser focus and a burning desire to grow the company.”

The company will be filing to change to a telecommunications classification. Cox stated, “I think the telecom sector will be one of the fastest growth sectors due to mobile wallets, blockchain technology and digital crypto-currency. This will create more dependence on our smartphones and connectivity. Look at the ICOs and what is going on around the world. I have already hired a lead programmer to help develop our digital stratagem worldwide.”

Cox also promised to catch the company up on its filings and keep them current, noting, “I believe you conduct yourself today, how you would like to be tomorrow, which is why KSIX will operate as if it were a blue chip company starting now.”

“We also want to connect with our shareholders by creating an environment where people can invest not only in the analytics of the company, but get to know us and be involved in our growth. To that end we are creating a company blog, newsletter, videos with question and answer sessions to keep our shareholders updated on our progress and direction. This momentum is now action based and it is no longer a story of what we will do……but what we are doing.”

For any questions regarding the agreement, please email invest@gotruewireless.com or call 901-687-7895.

ABOUT KSIX MEDIA HOLDINGS
KSIX Media Holdings, Inc. (OTCBB: KSIX), a Las Vegas based company, helps companies make more profit by utilizing proprietary software and intellectual property to leverage social media marketing to help grow the online presence and sales of clients while reducing cost per acquisition. KSIX also provides perform based traffic and sales via ad network distribution.

ABOUT TRUE WIRELESS, LLC
True Wireless LLC, an Oklahoma based company, is a nationwide wireless carrier with the ability to provide service over all 4 major USA wireless backbones. True is a licensed eligible telecommunications carrier (OK, AR, MD, RI and TX) providing discounted and subsidized wireless (cell phone) and broadband service through the National Broadband Program.

About Brian Cox
Brian Cox has been the majority owner and CEO of True Wireless since January, 2011. True Wireless has been a leader and innovator in the lifeline and now national broadband initiative space. Mr. Cox got his start in telecom in 2004 when he founded his first telephone company. Through organic growth and acquisition, he grew the company to the largest prepaid home phone company in the country and sold it in late 2009.

Mr. Cox is a minority partner, investor and or stakeholder in several other technology companies including telecom, wireless and network transactions using blockchain programming with digital currencies. Mr. Cox is also passionate about the growth of his foundation for the advancement of lower income children based in Memphis, TN.

Mr. Cox has a proven track record of not only success but winning. Many aspects of his leadership style are contributed to what he learned on the football field while earning Team Captain and All-Conference honors at Murray State University while majoring in Economics.

FORWARD LOOKING STATEMENTS
Certain statements in this release, other than statements of historical fact, may include forward-looking information that involves various risks and uncertainties. There can be no assurance that such forward-looking statements will prove to be accurate. Actual result and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change, other than as required pursuant to applicable securities laws.

KSIX Media Holdings, Inc.
invest@gotruewireless.com
901-687-7895

Source: KSIX Media Holdings, Inc.

Opiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug Delivery Technology

SANTA MONICA, Calif., June 28, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced a global, exclusive licensing agreement providing Opiant access to Aegis’ Intravail® drug delivery technology for all of Opiant’s opioid antagonist compounds. Financial terms were not disclosed.

“We are fortunate to be able to access Aegis’ proprietary Intravail® drug delivery technologies for applications that may benefit patients with addictions and eating disorders,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Aegis’ Intravail® can improve the absorption of drugs delivered nasally and has been designated generally recognized as safe (GRAS).”

Edward T. Maggio, Chief Executive Officer of Aegis added, “The Intravail® non-invasive absorption enhancement technology is particularly well suited for the treatment of chronic relapsing brain diseases and will help ensure that Opiant Pharmaceuticals maintains its leaderhip position in this field. We are excited to support these important programs.”

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

About Aegis Therapeutics  

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Its Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Its ProTek® excipients stabilize, prevent aggregation and reduce unwanted immunogenicity and anaphylaxis of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs. For more information, please visit www.aegisthera.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
Investor.relations@opiant.com

Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902

Source: Opiant Pharmaceuticals, Inc.

            © 2017 GlobeNewswire, Inc.

KSIX Media Holdings Announces Shareholder Update-Carter Matzinger, KSIX CEO updates shareholders on True Wireless Merger Transaction and Ongoing Operations

LAS VEGAS, NV — (Marketwired) — 07/17/17 — KSIX Media Holdings, Inc. (OTCBB: KSIX), a diversified media and internet company headquartered in Las Vegas, announce today a shareholder update.

Dear Shareholders:

I am excited to communicate that KSIX has made significant progress in the merger transaction with True Wireless and growing our core media business. I am also pleased to report, as notified in a recent 8k, we have selected new auditors in an effort to expedite all of our OTC filing requirements. This past Friday, we published a pre 14C to increase the authorized shares from 100m to 500m. This is a necessary step in our strategic plan for near future expansion and acquisitions.

Regarding the True Wireless acquisition, True Wireless CEO Brian Cox stated: “I feel we are literally just a few days away from having a signed equity contract. I have already engaged Roderfer, Moss and Co, PLLC to complete the precondition 2 year audits for closing. From an industry standpoint, the FCC recently posted an increased budget for the lifeline/broadband program at $2.2B for 2018. Internally, True Wireless was just under $1.2M revenue for June. There is palpable energy and momentum within our team and we are ready for the tasks ahead.”

As KSIX continues to grow, to better engage and inform our shareholders regarding our expansion activities, we are setting up new correspondence through email, video and social updates. All communication will be readily available on the Ksixmedia.com website so please check it often and sign up for instant alerts, updates and video events.

Sincerely,

Carter Matzinger, CEO KSIX Media Holdings

ABOUT KSIX MEDIA HOLDINGS KSIX Media Holdings, Inc. (OTCBB: KSIX) KSIX, a Las Vegas based company, has two operating divisions, DigitizeIQ and KSIX Media, Inc. DigitizeIQ provides digital advertising utilizing proprietary technology and intellectual properties designed to create new revenue streams and increase measurable audiences for clients. KSIX Media provides performance-based marketing via an advertising network that drives traffic and sales. KSIX manages offer tracking, reporting, and distribution on the third-party platform.

ABOUT TRUE WIRELESS, LLC True Wireless LLC, an Oklahoma based company, is a nationwide wireless carrier with the ability to provide service over all 4 major USA wireless backbones. True is a licensed eligible telecommunications carrier (OK, AR, MD, RI and TX) providing discounted and subsidized wireless (cell phone) and broadband service through the National Broadband Program.

FORWARD LOOKING STATEMENTS Certain statements in this release, other than statements of historical fact, may include forward-looking information that involves various risks and uncertainties. There can be no assurance that such forward-looking statements will prove to be accurate. Actual result and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change, other than as required pursuant to applicable securities laws.

Contact Information
KSIX Media Holdings, Inc
info@ksix.com
Source: KSIX Media Holdings, Inc

Investor Contact
OmniVance Advisors
PR@ksix.com
858-381-5740

Source: KSIX Media Holdings, Inc.

Pressure BioSciences’ Barocycler 2320EXTREME to be Featured in Multiple Presentations All Week at Major Scientific Meeting

Compelling Advantages of the Company’s Patented PCT Platform Highlighted in Two Different Mass Spectrometry User Meetings on Day One

SOUTH EASTON, MA — (Marketwired) — 06/06/17 — Pressure BioSciences, Inc. (OTCQB: PBIOD) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure cycling technology (“PCT”)-based sample preparation solutions to the worldwide life sciences industry, today announced that the Company’s patented PCT platform will be featured in multiple presentations at the annual conference of the American Society for Mass Spectrometry (“ASMS”), being held from June 4-8, 2017 in Indianapolis, IN.

Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI, said: “It is encouraging that in less than one year from the initial shipment of the Barocycler 2320EXT, the advantages of this next-generation PCT-based instrument will be highlighted in multiple presentations by well-respected scientific groups from around the world. These groups include researchers from such noteworthy institutions/companies as the U.S. Food and Drug Administration, Novo Nordisk A/S (Denmark), SCIEX (U.S. and Australia), ETH Zurich (Switzerland), the University of Cologne (Germany), and the Inova Schar Cancer Institute.

Dr. Lawrence continued: “Dr. Thomas Conrads, a nationally-acclaimed protein chemist, is the Associate Director of Scientific Technologies at the Inova Schar Cancer Institute. Dr. Conrads and his group were invited to participate in the SCIEX and ThermoFisher Scientific User Meetings on June 4th. During their presentations, they highlighted the use of the Barocycler 2320EXT for the digestion of tumor and other samples to be analyzed by their group as part of discovery proteomics for the APOLLO Consortium of the Cancer Moonshot program.”

“Proteins comprise most of the biomarkers that are measured to detect cancers, they constitute the antigens that drive immune response and the inter- and intra-cellular communications, and they are the drug targets for nearly every targeted therapy that is being evaluated in cancer trials today,” commented Dr. Conrads. “We believe that a combined systems biology view of the tumor microenvironment that orients cancer studies back to the functional proteome, phosphoproteome, and biochemistry of the cell will be essential to delivering on the promise of the Cancer Moonshot program.”

Dr. Conrads continued: “Standardized, reproducible, high quality preparation of samples to be analyzed is critical to the success of transformative research studies. We spent many months investigating multiple aspects of PCT-enhanced protein extraction and digestion. We subsequently concluded that PCT was an enabling tool that met our high standards for critical sample preparation. We also concluded that the PCT platform could make profiling of our laser micro-dissected tumor tissue samples possible at the throughput required by the APOLLO Consortium of the Cancer Moonshot program.”

Mr. Richard T. Schumacher, President and CEO of PBI, commented: “The ASMS Conference is one of the largest annual meetings of mass spectrometry professionals worldwide. At the 2016 ASMS Conference, we unveiled the newest addition to our PCT-based instrument line, the Barocycler 2320EXT. Designed with a number of new and enhanced features and benefits to enable scientists better access to biomolecules (e.g., proteins, lipids, nucleic acids) in samples being studied, we believe the 2320EXT offers the potential to result in new biological insights and discoveries, and rapid growth for PBI.”

Mr. Schumacher continued: “In February 2017, the Barocycler 2320EXT gained CE Mark approval, enabling it to be marketed throughout all 31 countries in the European Economic Area. In March 2017, the 2320EXT received the 2017 North American Excellence Award for ‘Best New Instrument for Sample Preparation’ by Corporate America News, a leading business publication. The Barocycler 2320EXT has become the centerpiece of our co-marketing agreement with global life sciences analytical technologies leader SCIEX. We believe it will continue to find a significant role in transformative research efforts worldwide, such as the Cancer Moonshot program.”

About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIOD) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 270 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

Forward Looking Statements Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts: Pressure BioSciences, Inc.

Richard T. Schumacher
President & CEO

Nate Lawrence
Vice President of Sales & Marketing

(508) 230-1828 (T)

Source: Pressure BioSciences, Inc.